Biomarkers: Early detection measures (Milestone 9.H)
Achieved
Timeline Start - End
2014 - 2022Research Implementation Area
BiomarkersLaunch research programs to develop and validate sensitive neuropsychological and behavioral assessment measures to detect and track the earliest clinical manifestations of AD and AD-related dementias.
Success Criteria
-
Development of at least one sensitive neuropsychological assessment measure that has been validated for the detection or tracking of the earliest clinical manifestations of AD and AD-related dementias.
-
Extend ongoing research on social and emotional functioning and decision-making in MCI/AD to identify early behavioral markers of disease.
-
Support research to develop clinical tools for assessment of early deficits in decision-making, motivation and social and emotional functioning in AD.
Summary of Key Accomplishments
NIA provided funding for the development of the Mobile Toolbox , a set of freely available smartphone tools to enhance self-administered cognitive tests. To date, the toolbox consists of two key projects:
- The MTB: A library of validated, smartphone enabled cognitive assessments;
- The M2C2: an assessment infrastructure for use in intensive longitudinal studies of cognitive change, with validated mobile tests that support widespread dissemination, use, and ongoing development by the research community.
NIA -supported projects are also studying social and emotional functioning, decision making, and driving behavior to identify early behavioral markers of cognitive decline.
The key accomplishments summary is current as of March 2022.
Accomplishments/Implementation Activities
Funding Initiatives
- RFA-AG-13-015: Alzheimer's Disease Prevention Trials (R01)
- PAR-14-089: Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- PAR-16-365: Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- PAR-18-175: Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- PAR-18-877: Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- RFA-AG-15-011: Biomarkers of Alzheimer’s Disease in Down Syndrome (R01)
- PAR-16-448: Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01)
- PAR-16-449: Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R21)
- PAR-16-364: Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- RFA-AG-17-052: Alzheimer's Disease Outcomes Research Resource (U2C)
- PAR-18-544: Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01/R21)
- PAR-18-538: Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R21)
- PAR-18-581: Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01)
- PAR-18-582: Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21)
- RFA-AG-18-012: Mobile Monitoring of Cognitive Change (U2C)
- RFA-AG-20-050: Low Cost Detection of Cognitive Decline in Clinical Settings (R61/R33)
- RFA-AG-20-051: Low Cost Detection of Cognitive Decline in Clinical (R01)
- NOT-AG-20-040: Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimer’s Disease and Related Dementias
- RFA-AG-20-022: Aging, Driving and Early Detection of Dementia (R01 Clinical Trial Optional)
- NOT-AG-21-048: Digital Technology for Early Detection and Monitoring of Alzheimer's Disease and Related Dementias
Research Programs and Resources
- Alzheimer’s Biomarkers Consortium – Down Syndrome (ABC-DS)
- NIA Ongoing Alzheimer’s and Related Clinical Trials and Studies
- Alzheimer’s Prevention Initiative (API)
- Anti-Amyloid Treatment In Asymptomatic Alzheimer’s Disease Study (A4 study)
- Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention Trial (DIAN-TU)
- The Mobile Toolbox for Monitoring Cognitive Function
- ADNI Psychometrics
- Predictors of Severity in Alzheimer’s Disease
- Optimizing Cognitive Assessment in DIAN with Smartphone-based Burst Testing
- Novel Automated Performance-based ADL Outcomes For Early AD Clinical Trials
- Neurodegeneration In Aging Down Syndrome (NiAD): A Longitudinal Study Of Cognition And Biomarkers of Alzheimer's Disease
- Biomarkers of Alzheimer's Disease In Adults With Down Syndrome
- Clinical Trials to Prevent Alzheimer’s Disease in Down Syndrome
- Emotional Function in Normal Aging and/or MCI and AD/ADRD
- Mobile Toolbox Website
- Research Network on Decision Neuroscience and Aging